Drug Pricing
Drug Pricing
Advancing Innovation and Access
We analyze the value that therapies bring to patients and develop novel payment models for rewarding innovation while restraining costs.
Featured Research
Most Medicare Beneficiaries May Pay More for Drugs Under the IRA
Part D plans are abruptly shifting more costs onto beneficiaries as they adjust to the IRA’s new cap on out-of-pocket spending.
Experts: Erin Trish
Related Subtopics
The Schaeffer Center is a nationally recognized leader on drug pricing research, with a particular focus on the economic system that distributes and pays for drugs. Our experts develop effective strategies for containing costs while rewarding new treatments based on the value they provide to patients.
Top Drug Pricing Stories View All
Perspective
When Cost-Effectiveness Thresholds Drift: Global HTA, MFN Pricing, and the Need for a Coherent Framework
Featured Experts: William Padula
In The News View All
Pink Sheet
Chen warns MFN could have unintended consequences and highlights need for US value-based pricing
Featured Experts: Alice Chen
MinnPost
Mulligan explains how 340B program encourages hospitals to favor more expensive drugs
Featured Experts: Karen Mulligan
Bloomberg
Lakdawalla explains why MFN could hold back new treatments in Europe
Featured Experts: Darius Lakdawalla
The Washington Post
Padula outlines possible factors driving a recent decline in prescription drug costs
Featured Experts: William Padula
Healthcare Dive
Blum discusses how staffing challenges at CMS could affect agency work on major initiatives
Featured White Paper
Mitigating the IRA’s Adverse Impacts on the Prescription Drug Market
Although the Inflation Reduction Act of 2022 (IRA) aimed to increase patient access to prescription drugs and decrease spending, researchers warn that it may have unintended negative impacts on patients in the long run. A Schaeffer Center white paper recommends three strategies to mitigate adverse impacts of the IRA.
Read the White PaperTeam View All Drug Pricing Experts
